BioWorld

June 17, 2004

More Development 'Unlikely' After Neurogen's RA Drug Phase II Miss

Another round of disappointing data for NGD 2000-1 caused Neurogen Corp.'s stock to drop nearly 19 percent Wednesday, and made further development of the product in rheumatoid arthritis an unlikely plan. (BioWorld Today) Read More

Metabasis Prices IPO: $35M Helps Liver Product Pipeline

Santarus Gets FDA Approval For Rapinex Powder Version

Advanced Magnetics' Phase III Ferumoxytol Study Under Way

Axonyx Begins Second Pivotal Phenserine Trial In Alzheimer's

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...